99 related articles for article (PubMed ID: 32749556)
1. Correction to: Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).
Hishiki T; Matsumoto K; Ohira M; Kamijo T; Shichino H; Kuroda T; Yoneda A; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Kaneko T; Hara J; Kaneko M; Ikeda H; Tajiri T; Nakagawara A;
Int J Clin Oncol; 2020 Sep; 25(9):1744-1745. PubMed ID: 32749556
[TBL] [Abstract][Full Text] [Related]
2. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).
Hishiki T; Matsumoto K; Ohira M; Kamijo T; Shichino H; Kuroda T; Yoneda A; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Kaneko T; Hara J; Kaneko M; Ikeda H; Tajiri T; Nakagawara A;
Int J Clin Oncol; 2018 Oct; 23(5):965-973. PubMed ID: 29700636
[TBL] [Abstract][Full Text] [Related]
3. Results of a prospective clinical trial JN-L-10 using image-defined risk factors to inform surgical decisions for children with low-risk neuroblastoma disease: A report from the Japan Children's Cancer Group Neuroblastoma Committee.
Iehara T; Yoneda A; Yokota I; Takahashi H; Teramukai S; Kamijyo T; Nakazawa A; Takimoto T; Kikuta A; Yagyu S; Ikeda H; Nakagawara A; Tajiri T;
Pediatr Blood Cancer; 2019 Nov; 66(11):e27914. PubMed ID: 31342649
[TBL] [Abstract][Full Text] [Related]
4. Validity of image-defined risk factors in localized neuroblastoma: A report from two centers in Western Japan.
Fumino S; Kimura K; Iehara T; Nishimura M; Nakamura S; Souzaki R; Nishie A; Taguchi T; Hosoi H; Tajiri T
J Pediatr Surg; 2015 Dec; 50(12):2102-6. PubMed ID: 26388125
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma.
Nakagawara A; Li Y; Izumi H; Muramori K; Inada H; Nishi M
Jpn J Clin Oncol; 2018 Mar; 48(3):214-241. PubMed ID: 29378002
[TBL] [Abstract][Full Text] [Related]
6. [Present status of neuroblastoma mass screening in Japan. Neuroblastoma-Committee of the Japanese Childhood Cancer Society].
Sawada T; Nagahara N; Ohi R; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Ohkawa H; Tunoda A
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2319-26. PubMed ID: 2260868
[TBL] [Abstract][Full Text] [Related]
7. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
8. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
9. [A preliminary treatment report of the Study Group of Japan for Advanced Neuroblastoma].
Sawaguchi S; Kaneko M; Nakajo T; Sawada T; Takahashi H; Tsuchida Y
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):1020-6. PubMed ID: 2674308
[TBL] [Abstract][Full Text] [Related]
10. Mass screening for neuroblastoma in Japan. Committee of the Neuroblastoma Mass Screening Study of the Japanese Society of Pediatric Oncology.
Sawada T; Nagahara N; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Okawa H; Tsunoda A; Sakurai M
Acta Paediatr Jpn; 1990 Dec; 32(6):725-33. PubMed ID: 2082676
[TBL] [Abstract][Full Text] [Related]
11. At the frontier of progress for paediatric oncology: the neuroblastoma paradigm.
Moreno L; Marshall LV; Pearson AD
Br Med Bull; 2013; 108():173-88. PubMed ID: 24211816
[TBL] [Abstract][Full Text] [Related]
12. How to deal with advanced cases of neuroblastoma detected by mass screening: a report from the Pediatric Oncology Study Group of the Kyushu area of Japan.
Suita S; Zaizen Y; Yano H; Akiyama H; Sera Y; Takamatsu H; Ueda K; Tasaka H; Miyazaki S; Kawakami K
J Pediatr Surg; 1994 May; 29(5):599-603. PubMed ID: 8035266
[TBL] [Abstract][Full Text] [Related]
13. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.
Brodeur GM; Seeger RC; Barrett A; Berthold F; Castleberry RP; D'Angio G; De Bernardi B; Evans AE; Favrot M; Freeman AI
J Clin Oncol; 1988 Dec; 6(12):1874-81. PubMed ID: 3199170
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Tushabe DA; Berthold F
Cochrane Database Syst Rev; 2015 Jan; 1():CD010685. PubMed ID: 25634649
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol.
Navarro S; Amann G; Beiske K; Cullinane CJ; d'Amore ES; Gambini C; Mosseri V; De Bernardi B; Michon J; Peuchmaur M;
J Clin Oncol; 2006 Feb; 24(4):695-9. PubMed ID: 16446343
[TBL] [Abstract][Full Text] [Related]
16. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.
Shimada H; Ambros IM; Dehner LP; Hata J; Joshi VV; Roald B
Cancer; 1999 Jul; 86(2):349-63. PubMed ID: 10421272
[TBL] [Abstract][Full Text] [Related]
17. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
18. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.
Owens C; Irwin M
Crit Rev Clin Lab Sci; 2012; 49(3):85-115. PubMed ID: 22646747
[TBL] [Abstract][Full Text] [Related]
19. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
Yanik GA; Parisi MT; Naranjo A; Nadel H; Gelfand MJ; Park JR; Ladenstein RL; Poetschger U; Boubaker A; Valteau-Couanet D; Lambert B; Castellani MR; Bar-Sever Z; Oudoux A; Kaminska A; Kreissman SG; Shulkin BL; Matthay KK
J Nucl Med; 2018 Mar; 59(3):502-508. PubMed ID: 28887399
[TBL] [Abstract][Full Text] [Related]
20. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.
Castleberry RP; Cantor AB; Green AA; Joshi V; Berkow RL; Buchanan GR; Leventhal B; Mahoney DH; Smith EI; Hayes FA
J Clin Oncol; 1994 Aug; 12(8):1616-20. PubMed ID: 8040674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]